Basel, Switzerland, September 18, 2023
- CEO Pierre-Alain Ruffieux to leave Lonza
- Albert M. Baehny to step in as CEO ad interim
- Capital Markets Day on October 17 confirmed.
Lonza announced today that Pierre-Alain Ruffieux, CEO, will leave the company at the end of September by mutual agreement. The Board of Directors also announced that Albert M. Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is appointed.
The medium-term strategy and outlook will be discussed in detail at the Capital Markets Day in Visp on 17th October 2023.
Christoph Maeder, Lead Independent Director and Vice-Chairman, Lonza, said: “Albert has agreed to lead the Company as CEO on a temporary basis until a successor is in place, for which the Board thanks him. The search for a permanent CEO will start soon. The Board would like to thank Pierre-Alain for his service to Lonza and wishes him well in his future endeavors.”
Albert M. Baehny, Chairman, Lonza, said: “I am committed to Lonza, our employees and all stakeholders. While recent months have undoubtedly been challenging, the company is a global leader in our industry and has many opportunities for further growth across all our businesses. In the months ahead, I will ensure that we are optimally positioned to fully capture those opportunities and I look forward to working with my Board and Executive Committee colleagues.”
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our unparalleled breadth of offerings across divisions enables our customers to commercialize their discoveries and innovations in the healthcare industry.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17500 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 922 million in Half-Year 2023. Find out more at